-
Neuralstem Sees Breakthrough In Spinal Cord Injury
Neuralstem’s FDA-approved NSI-566/chronic spinal cord injury clinical trial, expected to commence in the second half of 2013, is explored and its four U.S. centers named, in this expansive article. It includes reference to the company’s planned 2013 acute SCI trial in South Korea, and cites promising preclinical SCI animal data published recently in Stem Cell Research & Therapy, and additional SCI data published by science journal, Cell, last year.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.